Indication
treatment of advanced renal cell carcinoma (RCC) in treatment-naïve adults with intermediate or poor risk per IMDC criteria

Medicine details

Medicine name:
cabozantinib (Cabometyx)
SMC ID:
SMC2136
Pharmaceutical company
Ipsen Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Resubmission
Status
Advice due date:
11 February 2019
SMC meeting date:
08 January 2019
Patient group submission deadline:
03 December 2018